Skip to main navigation

Top bar

Biogen.com Information Request Sign up for Alerts Search

Investor Relations

Overview

News

Events Presentations

SEC Filings Annual Reports

Stock Quote & Chart Analyst Coverage Investor FAQs

Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board

News

News

News Category

Year

November 2, 2017

Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

November 1, 2017

The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy

October 30, 2017

Biogen to Present at the Clinical Trials on Alzheimer’s Disease Conference

October 27, 2017

Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product

October 25, 2017

Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

October 24, 2017

Biogen Reports Quarterly Revenues of $3.1 Billion

October 24, 2017

Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

October 23, 2017

Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer’s Disease Treatments Including Phase 3 Aducanumab

October 18, 2017

Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach

October 5, 2017

Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy

Pagination

First page
Previous page
…
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
…
Next page
Last page

Displaying 101 - 110 of 678

Footer

Investors
Careers
Our Stories
Contact Us

Follow us

Bottom

Privacy Policy
Terms & Conditions
Forward-Looking Statements
Community Guidelines

Investor Relations

Overview

News

Events & Presentations

Events
Presentations

Financials

SEC Filings
Annual Reports

Stock Information

Stock Quote & Chart
Analyst Coverage
Investor FAQs

Corporate Governance

Governance Documents
Committee Composition & Charters
Leadership
Code of Business Conduct
Contact the Board

Top bar

Biogen.com

Information Request

Sign up for Alerts

Search

Follow us